Overview

Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To compare the antiviral efficacy and safety of a 12-week with a 24-week treatment of BI 201335 at a dose of 120 mg once daily, with a 24-week background of pegylated interferon-alpha 2a (PegIFN) plus ribavirin (RBV), in treatment-naïve patients infected with hepatitis C virus (HCV) genotype 1

Phase:

Phase 2

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin